LTR Pharma Ltd (LTP) - Net Assets
Based on the latest financial reports, LTR Pharma Ltd (LTP) has net assets worth AU$31.51 Million AUD (≈ $22.30 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$32.21 Million ≈ $22.79 Million USD) and total liabilities (AU$700.57K ≈ $495.70K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does LTR Pharma Ltd carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$31.51 Million |
| % of Total Assets | 97.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 444.21 |
LTR Pharma Ltd - Net Assets Trend (2021–2025)
This chart illustrates how LTR Pharma Ltd's net assets have evolved over time, based on quarterly financial data. Also explore LTR Pharma Ltd total assets for the complete picture of this company's asset base.
Annual Net Assets for LTR Pharma Ltd (2021–2025)
The table below shows the annual net assets of LTR Pharma Ltd from 2021 to 2025. For live valuation and market cap data, see LTR Pharma Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$31.51 Million ≈ $22.30 Million |
+971.57% |
| 2024-06-30 | AU$2.94 Million ≈ $2.08 Million |
+41.89% |
| 2023-06-30 | AU$2.07 Million ≈ $1.47 Million |
+17.12% |
| 2022-06-30 | AU$1.77 Million ≈ $1.25 Million |
+4436.59% |
| 2021-06-30 | AU$-40.80K ≈ $-28.87K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LTR Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1264423700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$44.11 Million | 139.99% |
| Other Components | AU$82.92K | 0.26% |
| Total Equity | AU$31.51 Million | 100.00% |
LTR Pharma Ltd Competitors by Market Cap
The table below lists competitors of LTR Pharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chi Sheng Chemical
TWO:4111
|
$55.33 Million |
|
Jorjin Technologies
TWO:4980
|
$55.33 Million |
|
Inv Tricahue
SN:TRICAHUE
|
$55.34 Million |
|
UAC Global Public Company Limited
BK:UAC
|
$55.35 Million |
|
Flagship Minerals Ltd
AU:FLG
|
$55.27 Million |
|
Budi Starch & Sweetener Tbk
JK:BUDI
|
$55.27 Million |
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
$55.26 Million |
|
Rushil Decor Limited
NSE:RUSHIL
|
$55.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LTR Pharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,940,610 to 31,510,890, a change of 28,570,280 (971.6%).
- Net loss of 5,593,560 reduced equity.
- Other factors increased equity by 34,163,840.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-5.59 Million | -17.75% |
| Other Changes | AU$34.16 Million | +108.42% |
| Total Change | AU$- | 971.58% |
Book Value vs Market Value Analysis
This analysis compares LTR Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | AU$0.00 | AU$0.43 | x |
| 2022-06-30 | AU$0.01 | AU$0.43 | x |
| 2023-06-30 | AU$0.01 | AU$0.43 | x |
| 2024-06-30 | AU$0.02 | AU$0.43 | x |
| 2025-06-30 | AU$0.17 | AU$0.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LTR Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -265.90%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.02x
- Recent ROE (-17.75%) is above the historical average (-76.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-36.72K |
| 2022 | -58.05% | -11020.60% | 0.00x | 1.27x | AU$-1.20 Million |
| 2023 | -70.20% | -1616566.67% | 0.00x | 1.01x | AU$-1.66 Million |
| 2024 | -236.50% | -14097.89% | 0.01x | 1.15x | AU$-7.25 Million |
| 2025 | -17.75% | -265.90% | 0.07x | 1.02x | AU$-8.74 Million |
Industry Comparison
This section compares LTR Pharma Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,810,720
- Average return on equity (ROE) among peers: -71.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LTR Pharma Ltd (LTP) | AU$31.51 Million | 0.00% | 0.02x | $55.29 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About LTR Pharma Ltd
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australi… Read more